Companies Jockey for Position in Crowded Hepatitis C Market
The "blockbuster" drug model may still have some life in it yet. That's what a number of big pharma and "blue chip" biotechs are hoping anyway as they invest millions of research dollars in their quests to develop the next generation of hepatitis C virus (HCV) drugs. The potential market for HCV drugs is predicted to grow rapidly in the next five years and could get even get bigger following recent draft guidelines from the Centers for Disease Control and Prevention (CDC) proposing that all U.S. baby boomers get a one-time test for the hepatitis C virus.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter